26 related articles for article (PubMed ID: 35902297)
1. Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G; Floquet A; Tredan O; Carrot A; Langlois-Jacques C; Lopez J; Selle F; Abdeddaim C; Leary A; Dubot-Poitelon C; Fabbro M; Gladieff L; Lamuraglia M
Nat Commun; 2024 Jun; 15(1):4753. PubMed ID: 38834579
[No Abstract] [Full Text] [Related]
2. British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer.
Sundar S; Nordin A; Morrison J; Wood N; Ghaem-Maghami S; Nieto J; Phillips A; Butler J; Burton K; Gornall R; Dobbs S; Glasspool R; Peevor R; Ledermann J; McNeish I; Ratnavelu N; Duncan T; Frost J; Lim K; Michael A; Brockbank E; Gajjar K; Taylor A; Bowen R; Andreou A; Ganesan R; Nicum S; Edmondson R; Clayton R; Balega J; Rolland P; Maxwell H; Fotopoulou C
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672287
[TBL] [Abstract][Full Text] [Related]
3. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Capoluongo ED; Pellegrino B; Arenare L; Califano D; Scambia G; Beltrame L; Serra V; Scaglione GL; Spina A; Cecere SC; De Cecio R; Normanno N; Colombo N; Lorusso D; Russo D; Nardelli C; D'Incalci M; Llop-Guevara A; Pisano C; Baldassarre G; Mezzanzanica D; Artioli G; Setaro M; Tasca G; Roma C; Campanini N; Cinieri S; Sergi A; Musolino A; Perrone F; Chiodini P; Marchini S; Pignata S
ESMO Open; 2022 Oct; 7(5):100585. PubMed ID: 36156447
[TBL] [Abstract][Full Text] [Related]
4. "DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies.
Wilczyński JR; Wilczyński M; Paradowska E
Front Oncol; 2023; 13():1201497. PubMed ID: 37448521
[TBL] [Abstract][Full Text] [Related]
5. Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms.
Yang S; Fei W; Zhao Y; Wang F; Ye Y; Wang F
Int J Nanomedicine; 2023; 18():3035-3046. PubMed ID: 37312935
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).
Chekerov R; Arndt T; Pietzner K; Canzler U; Wimberger P; Strauß HG; Mahner S; Woelber L; de Gregorio N; Stocker G; von Abel E; Neunhoeffer T; Belau AK; Mustea A; Yalinkaya I; Braicu EI; Richter R; Sehouli J;
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7637-7649. PubMed ID: 37000264
[TBL] [Abstract][Full Text] [Related]
8. Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.
Davidson BA; Secord AA
Int J Womens Health; 2014; 6():289-300. PubMed ID: 24648773
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Joly F; Fabbro M; Berton D; Lequesne J; Anota A; Puszkiel A; Floquet A; Vegas H; Bourgeois H; Bengrine Lefevre L; You B; Pommeret F; Lortholary A; Spaeth D; Hardy-Bessard AC; Abdeddaim C; Kaminsky-Forrett MC; Tod M; Kurtz JE; Del Piano F; Meunier J; Raban N; Alexandre J; Mouret-Reynier MA; Ray-Coquard I; Provansal Gross M; Brachet PE
Gynecol Oncol; 2022 Sep; 166(3):389-396. PubMed ID: 35902297
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Morgan RD; Banerjee S; Hall M; Clamp AR; Zhou C; Hasan J; Orbegoso C; Taylor S; Tugwood J; Lyon AR; Dive C; Rustin GJS; Jayson GC
Gynecol Oncol; 2020 Mar; 156(3):545-551. PubMed ID: 31932108
[TBL] [Abstract][Full Text] [Related]
13. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
